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CASE REPORT

Temozolomide for Relapsed Primary CNS Lymphoma
Asif Husain Osmani and Nehal Masood

ABSTRACT
Primary CNS lymphoma (PCNSL) is an aggressive form of non-Hodgkin's lymphoma that accounts for 3% of all primary
brain tumours. No clear risk factors for PCNSL in immunocompetent patients are known. The disease is more common
in men and in elderly persons. Patients with AIDS who have low CD4+ counts are at the greatest risk for PCNSL. Virtually
all PCNSLs in patients with AIDS express an Epstein-Barr virus (EBV)-related genome. PCNSL is less frequently
associated with EBV in patients without AIDS. A 42 years old gentleman diagnosed with primary CNS lymphoma with
negative serological test for human immunodeficiency virus was initially treated with Modified De Angelis protocol relapsed
after treatment. He underwent gamma knife stereotactic surgery which lead to further deterioration clinically and
progression of disease on imaging. Later, he was treated with salvage high dose methotrexate, but after completion of six
cycles there was a radiological progression of disease. Relapsed disease was further treated with a single agent
temozolomide and the disease went in remission.
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INTRODUCTION
Primary CNS lymphoma accounts for 3% of all primary
brain tumours with median age of onset of about 62
years.1 The disease is more common in men (the maleto-female ratio is 2:1). The nature, intensity, and duration
of immune suppression are factors in determining the
risk of developing PCNSL. Patients with AIDS who have
low CD4+ counts are at the greatest risk for PCNSL. It is
an aggressive form of non-Hodgkin's lymphoma that
develops within brain, spinal cord, eye or leptomeninges
without evidence of systemic involvement. In majority of
the cases, it presents as unifocal and multifocal
enhancing lesions on MRI, frequently adjacent to
ventricles. Biopsy is the diagnostic procedure of choice
revealing high-grade malignant non-Hodgkin’s B-cell
lymphoma in more than 90% cases. Pathologically, it is
an angiocentric neoplasm composed of a dense
monoclonal proliferation of lymphocytes usually diffuse
large B cells.2 Despite recent progress, results following
the treatment for primary CNS lymphoma patients
remain disappointing, typically producing a 5 years
survival rate of 22-40%.3 Chemotherapy followed by
radiotherapy is the cornerstone of first line treatment of
primary CNS lymphoma.4,5 The principal agent in its
management is high dose methotrexate (HD MTX)
which yields 30-65% complete responses.6 As no other
simple agent is prospectively proven active against
primary CNS lymphoma, it is presently impossible to
attribute a therapeutic benefit of any single agent apart
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from HD MTX. Temozolomide is an oral alkylating agent
that spontaneously undergoes clinical conversion of the
cytotoxic metabolite MTIC (5-[3-methyl-1-triazeno]
imidazole-4-carboxamide) at physiological Ph, without
metabolic conversion. Temozolomide depletes methyltransferase in various cell types. Temozolomide activity
against primary CNS lymphoma has been (anecdotally)
reported.7
We present a case of primary CNS lymphoma which
progressed on various chemotherapy regimens but
responded to a single agent temozolomide.

CASE REPORT
A 42 years old gentleman with no medical or family
history presented to Emergency Room in 2007 with a
single episode of generalized tonic clonic seizures
followed by unconsciousness. After regaining consciousness there was no neurological deficit and no lymph
nodes palpable on examination.
The full blood count, calcium, urea, electrolytes and liver
function test were within normal range and the
serological test for human immunodeficiency virus was
negative. MRI brain showed a tumour in the right
temporal region.
The CT scan of neck, chest, abdomen and pelvis were
normal. Craniotomy and biopsy of lesion was consistent
with primary diffuse large B cell lymphoma (high grade).
Tumour showed LCA, CD 20, CD 3 positivity with MIB 1
positive in approximately 90% of neoplastic cell.
The patient was treated with Modified De Angelis
protocol for primary CNS lymphoma. After completion of
therapy, the MRI brain showed increase in size of lesion
in the occipital horn of right ventricle and another on left
side (progression) of disease. In one month, the patient
developed right hemiplegia and aphasia. Patient's family
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took the option of gamma knife stereotactic surgery,
which lead to further deterioration of his symptoms.
Subsequently he was treated with salvage high dose
methotrexate. Patient improved clinically after two
cycles and MRI also showed responsive disease. After
completion of six cycles imaging showed slight
progression of disease (Figure 1A). At this time he was
switched to salvage temozolomide 150 mg/m2 per orally
daily for 5 days a month.10 After three cycles imaging
showed complete resolution of disease, but patient was
experiencing frequent episode of headaches, so the
dose of temozolomide was decreased to 100 mg/m2. On
completion of his tenth cycle the brain imaging again
showed resolution of disease (Figure 1B).

Temozolomide has also been effective as a single agent
as salvage therapy in relapse primary CNS lymphoma.
In a phase-2 trial assessing the activity of TMZ with
recurrent primary CNS lymphoma, previously treated
with HD-MTX containing chemotherapy and radiotherapy, 9 out of 36 patients had a complete response
(25%; 95% CI 11-39%) and 2 had a partial response
(6%; 95% CI 0-14%). The study was closed at this time
as the target of 10 objective responses were achieved.
Median progression-free survival was 2.8 months
(interquartile range 1-8 months), median overall survival
was 3.9 months (interquartile range 1.7-16 months) and
1-year overall survival was 31% (95% confidence
interval 16-46%).10 In this study 28 patients (78%) had
first recurrence and only 8 patients had multiple
recurrent disease having failed to respond to other
salvage treatment. Median number of cycles were 2
(range 1-12). Toxicities were mild; 2 patients had
1 episode of grade 4 neutropenia and 1 patient had
grade 3 vomiting in a single cycle. None of the patients
had headaches.

The patient remained in remission 3 years from his initial
presentation and has a good quality of life. He has no
neurological deficit, has normal mental functions and is
not dependant for daily chores.

Single-agent temozolomide can be considered as
salvage treatment for patients with primary CNS
lymphoma. It is well tolerated in even patients with
poor performance status. Its non-cumulative and
modest toxicities makes it potentially useful agent for
maintenance therapy.
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